SecBot SecBot
8-K ·Filed Jun 12, 2026

MCK

MCKESSON CORP
NEUTRAL
Impact 5/10
Horizonmonths Processed5mo ago SEC0000927653-26-000167
8-K material event: Items 1.01
Actionable Insight • Neutral

The addition of $2.25B in term debt to the medical-surgical subsidiary signals progress toward the planned spin-off from McKesson Corp (MCK). For MCK shareholders, this is a neutral operational step, leverage at the subsidiary increases but likely reflects the intended capital structure of the separated entity. Monitor the spin-off timeline and any credit rating actions on the subsidiary. The term loan's floating-rate exposure (SOFR+2.25%) creates modest interest cost sensitivity to Fed policy.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$784.05
T+0 close · Jun 12, 2026 · via day close
Latest settled
+13.40%
T+60 · $889.12
Vs SPY
+10.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $784.05entry
  2. T+1 · 5mo ago −0.54%α −2.31% · $779.78
  3. T+5 · 5mo ago −4.26%α −4.94% · $750.63
  4. T+20 · 4mo ago +2.79%α +1.01% · $805.96
  5. T+60 · 2mo ago +13.40%α +10.14% · $889.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

McKesson Corp subsidiary McKesson Medical-Surgical Top Holdings Inc. amended its April 2026 credit agreement to add a $2.25 billion senior secured Term B loan due 2032, with JPMorgan as sole lender. Proceeds will fund transaction costs and the broader spin-off/restructuring (the 'Transactions'). The facility carries an interest rate of SOFR + 2.25% (Term Benchmark) or Base Rate + 1.25% and is secured by substantially all assets of the borrower and its material US subsidiaries. This is a significant increase in subsidiary-level leverage but appears to be a planned component of the medical-surgical business separation from McKesson Corp.

Key Financial Metrics

Deal Type
credit_facility

Key Facts

  • $2.25 billion incremental senior secured Term B loan added to existing credit agreement for McKesson Medical-Surgical Top Holdings Inc.
  • Loan matures in 2032 (sixth anniversary of June 9, 2026 closing) and is priced at SOFR + 2.25% per annum (or Base Rate + 1.25%)
  • JPMorgan Chase Bank, N.A. is the sole Amendment No. 1 Term B Lender for this tranche
  • Proceeds are stated to be used to pay fees/expenses of the amendment and to fund the 'Transactions', likely including the planned spin-off of McKesson's medical-surgical business
  • Credit agreement contains financial covenants: maximum total net leverage ratio and minimum interest coverage ratio, with customary cure rights
  • Existing facilities under the same agreement: $750M Term A-1, $250M Term A-2, and $1.0B revolving credit facility remain in place

Financial Impact

Adds $2.25 billion in new senior secured term debt at the McKesson Medical-Surgical subsidiary, increasing total credit facility commitments under this agreement from ~$2.0 billion to ~$4.25 billion (including the undrawn revolver). Interest expense will increase by approximately SOFR + 2.25% on the drawn amount.

debtinterest expenseleverage

Risk Factors

  • Subsidiary leverage rises significantly with $2.25B new secured debt, increasing financial risk at the spun-off entity
  • Floating-rate exposure (SOFR + 2.25%) creates earnings sensitivity to interest rate increases
  • Execution risk around the broader spin-off and use of proceeds if the Transactions are delayed or restructured

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Analyst Consensus
87% bullish (23 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000927653-26-000167
Document: mck-20260609.htm0000927653-26-000167
Document: 0000927653-26-000167-index-headers.html0000927653-26-000167
Document: 0000927653-26-000167-index.html0000927653-26-000167
Document: 0000927653-26-000167.txt0000927653-26-000167

Track record

26 reports on MCK

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +22.92% at T+60 after the Apr 1, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago 144 Neutral 2/10 Entry $1,072.00 to $1,077.05 Now $1,105.04 +3.08% ▲ +0.47% −2.82% vs SPY
  2. Nov 4, 202612d ago 144 Neutral 2/10 Entry $1,072.00 to $1,077.05 Now $1,105.04 +3.08% ▲ +0.47% −2.82% vs SPY
  3. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $1,072.00 to $1,077.05 Now $1,105.04 +3.08% ▲ +0.47% −2.82% vs SPY
  4. Oct 30, 202617d ago 25-NSE Neutral 1/10 Entry $994.58 to $1,060.84 Now $1,105.04 +11.11% ▲ +6.66% +9.37% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $960.56 to $1,069.44 Now $1,105.04 +15.04% ▲ +11.34% +12.05% vs SPY
  6. Oct 27, 202620d ago GOVT-CONTRACT Neutral 3/10 Entry $960.56 to $1,069.44 Now $1,105.04 +15.04% ▲ +11.34% +12.05% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $955.76 to $1,010.43 Now $1,105.04 +15.62% ▲ +5.72% +7.21% vs SPY
  8. Oct 6, 20265w ago 8-K Bullish 6/10 Entry $921.67 to $961.88 Now $1,105.04 +19.90% ▲ +4.36% +4.50% vs SPY
  9. Sep 1, 202610w ago GOVT-CONTRACT Neutral 3/10 Entry $924.78 to $880.86 Now $1,105.04 +19.49% ▼ −4.75% −3.79% vs SPY
  10. Aug 28, 202611w ago 8-K Neutral 4/10 Entry $885.32 to $896.29 Now $1,105.04 +24.82% ▲ +1.24% +1.38% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026